Core Insights - Seer, Inc. announced a significant genome-wide association study (GWAS) published in Nature Genetics, demonstrating the importance of mass spectrometry in validating protein changes and establishing reliable drug targets and clinical biomarkers [1][10] Group 1: Study Overview - The GWAS involved approximately 1,600 blood samples from diverse ethnic backgrounds, with a discovery cohort of 1,260 and a replication cohort of 325, leading to the detection of 5,753 proteins and quantification of 1,980 proteins in at least 80% of participants [2] - Researchers identified 364 protein quantitative trait loci (pQTLs) associated with protein abundance, with 102 of these replicated in the independent cohort, including 35 previously unreported signals [3] Group 2: Methodology and Findings - Traditional affinity-based proteomics can produce erroneous signals due to epitope effects, where genetic variants alter binding sites, leading to false associations between protein expression and genetic variants [4] - The Proteograph's mass spectrometry approach allows for direct measurement of proteins at the peptide level, effectively mitigating confounding effects and confirming true biological changes [5][6] Group 3: Implications for Research and Development - The study emphasizes that mass spectrometry validation is crucial for ensuring the reliability of protein measurements, which can enhance drug discovery and biomarker development by reducing technical noise and increasing the likelihood of clinical success [9][10] - The findings suggest that datasets relying solely on affinity reagents may contain a significant number of false associations, underscoring the need for mass spectrometry validation in genetic association studies [6][7] Group 4: Future Directions - As proteomics integrates with genomics and clinical data, the accuracy of these datasets will be vital for supporting drug targets and translational medicine, positioning Seer to lead in population-scale proteomics [11]

Core Insights - Bicara Therapeutics announced early data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa in combination with pembrolizumab for first-line HPV-negative recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) [1][2] - The results indicate a high overall response rate and a safety profile consistent with the 1500mg dose, supporting ongoing pivotal trials [1][2] Company Overview - Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, with ficerafusp alfa as its lead program [11] - Ficerafusp alfa is a first-in-class bifunctional antibody designed to enhance tumor penetration by targeting both epidermal growth factor receptor (EGFR) and transforming growth factor beta (TGF-β) [9][11] Clinical Trial Data - In the efficacy evaluable population of 30 patients, the objective response rate was 57%, with 50% achieving partial responses and 7% achieving complete responses [6] - The disease control rate was reported at 83%, and complete neutralization of TGF-β1 was observed [6] - Safety findings were consistent with the known safety profile of ficerafusp alfa plus pembrolizumab in R/M HNSCC [6] Upcoming Events - Bicara Therapeutics will present the findings at the European Society for Medical Oncology (ESMO) Asia Congress on December 6, 2025, and will host a conference call and webcast on the same day [1][5][3]

Core Viewpoint - Targa Resources Corp. has entered into a definitive agreement to acquire Stakeholder Midstream, LLC for $1.25 billion in cash, enhancing its midstream infrastructure and cash flow generation capabilities in the Permian Basin [1][10]. Acquisition Details - The acquisition price of $1.25 billion represents approximately 6 times the estimated unlevered adjusted free cash flow for 2026 [10]. - Stakeholder operates natural gas gathering, treating, and processing services, along with crude gathering and storage services, featuring around 480 miles of natural gas pipelines and a processing capacity of approximately 180 million cubic feet per day [2][10]. - Stakeholder's assets are supported by long-term, fee-based contracts across approximately 170,000 dedicated acres, which exhibit low decline rates, ensuring a stable volume profile [2][10]. Financial Impact - Targa anticipates that Stakeholder will generate unlevered adjusted free cash flow of about $200 million annually, with minimal capital needs and low integration costs [3][10]. - The transaction is expected to have a limited impact on Targa's leverage ratio, maintaining it within the long-term target range of 3.0 to 4.0 times [7][10]. Strategic Fit - The acquisition is viewed as a strategic move to enhance Targa's existing operations, leveraging strong relationships with major producers in the region and complementing its sour gas treating and carbon capture capabilities [4][5][10]. - Targa's CEO emphasized that this transaction aligns with the company's strategy to create shareholder value through balance sheet strength and organic growth opportunities [4][5]. Transaction Timeline and Advisors - The completion of the acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to close in the first quarter of 2026 [7]. - RBC Capital Markets is serving as Targa's financial advisor, while Jefferies is acting as the exclusive financial advisor to Stakeholder [8].

TORONTO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Inventus Mining Corp. (TSXV: IVS) (“Inventus” or the “Company”) is pleased to report the results from its 007 North bulk sample at its wholly-owned Pardo Gold Project, located 65 km northeast of Sudbury, Ontario. Highlights A total of 427 ounces of gold recovered from 4,674 dry tonnes for a reconciled head grade of 3.04 gpt gold and a metallurgical recovery of 94%The cost of the bulk sample was approximately CAD$1,200,000 and the sale of the recoverable ounces was ...

Located just 7 km west of Filo del Sol in the Vicuña District, the 46 South target is at the south end of a 3 km N-S trending corridor of mineralization at Sobek Central The 46 South epithermal and underlying porphyry target sits on the margin of a district scale magnetic high where coincident mag-susceptibility, MT anomalies and ground-based IP responses lie directly below a large soil survey geochemical anomaly where hydrothermal and tourmaline breccias outcrop on surface In preparation for drilling a pro ...

Core Insights - AtlasClear Holdings, Inc. reported significant growth in October 2025, with revenue increasing by 128% year-over-year and net income rising by 169% [1][3][6] Financial Performance - October 2025 revenue reached $3,051,661, a 113% increase compared to $1,433,626 in October 2024 [6] - Net income for October 2025 was $940,268, up 169% from $349,447 in October 2024 [6] - Net capital as of October 31, 2025, was $14,935,193, reflecting a 40% year-over-year increase from $10,641,242 as of October 31, 2024 [6] Operational Highlights - Wilson-Davis, a subsidiary of AtlasClear, experienced elevated client activity and strong operating leverage, marking one of the strongest months since its acquisition [2][3] - The company is focused on building a modern, technology-forward clearing and banking platform, which is expected to drive future growth [3][4] Strategic Outlook - The management expressed confidence in the company's growth strategy and the opportunities ahead for 2026 and beyond, supported by recent financing and an improving capital position [3][4]

Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designat ...

Core Insights - Akebia Therapeutics has established a rare kidney disease pipeline, focusing on two main product candidates: AKB-097, a complement inhibitor, and praliciguat, an sGC stimulator [2][3] - The company plans to initiate Phase 2 clinical trials for both AKB-097 and praliciguat in 2026, targeting multiple rare kidney disease indications [1][3] Group 1: Product Candidates - AKB-097 is a tissue-targeted C3d-Factor H fusion protein complement inhibitor acquired from Q32 Bio, expected to address a range of complement-mediated rare kidney diseases [2][5] - Praliciguat is an oral sGC stimulator, with initial clinical trials focusing on focal segmental glomerulosclerosis (FSGS), a rare kidney disease [2][8] Group 2: Clinical Trials - The Phase 2 basket trial for AKB-097 is set to begin in the second half of 2026, with initial data expected in 2027 [6][3] - The Phase 2 trial for praliciguat will enroll up to 60 patients in the U.S., with the primary efficacy endpoint being the change in urine protein-to-creatinine ratio over 24 weeks [10][11] Group 3: Financial Aspects - Akebia paid an upfront fee of $7 million to Q32 Bio for the acquisition of AKB-097, with additional payments tied to development milestones and royalties on net sales [7]

KELOWNA, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70)(“Doseology” or the “Company”) is pleased to announce the launch of its Investor Communications Initiative, designed to strengthen disclosure practices, expand investor engagement, and support the Company’s long-term commercial and capital-markets strategy. The program includes a three (3) month engagement with Guerilla Capital, with an option to renew, along with a one (1) year digital ...

Core Insights - Quantum BioPharma Ltd. is involved in a USD $700 million lawsuit against CIBC and RBC, alleging stock market manipulation through "stock spoofing" [2][3] - The company emphasizes the importance of addressing stock market manipulation for the benefit of shareholders and the integrity of publicly traded companies [3] Company Overview - Quantum BioPharma is a biopharmaceutical company focused on innovative treatments for neurodegenerative and metabolic disorders, including multiple sclerosis (MS) [4] - The company is developing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation in MS [4] - Quantum BioPharma retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is associated with its product unbuzzd™ and has a royalty agreement that could yield up to $250 million [4] Legal and Regulatory Context - The investigative series by CTV News highlights a trend of increasing market manipulation cases in Canada, underscoring the relevance of Quantum BioPharma's legal actions [2][3] - The company is actively encouraging whistleblowers to come forward with information regarding illegal market manipulation, offering rewards up to USD $7 million [3]